CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs
22/4 19:55
(RTTNews) - CERo Therapeutics Holdings, Inc. (CERO), a biotech company focused on next-generation engineered T cell immunotherapies using phagocytic mechanisms, has announced a securities purchase agreement for a new convertible preferred stock offering....